Molecular Evidence (rationale) for VEGF targeted therapy in iMCD patients:

  • “VEGF is frequently elevated in iMCD. VEGF, which promotes cell survival, angiogenesis, and vascular permeability, is often elevated in parallel with iMCD symptoms” (Blood 2014)

Case Reports of anti-VEGF therapy for iMCD patients:

Sirolimus (Rapamycin) is an mTOR inhibitor that blocks VEGF expression by inhibiting mTOR.

  • To learn more about sirolimus as treatment for iMCD, please click here.

Clinical Trials targeting VEGF in iMCD:

No clinical trials targeting VEGF in iMCD patients have been conducted.

Arrow Shape Facebook Instagram Twitter Youtube Play Arrow Left